PierianDx
St Louis
About PierianDx
PierianDx is catalyzing global adoption of genomic sequencing in healthcare by empowering physicians in the laboratory and clinic to more effectively diagnose and treat patients with cancer and other complex diseases. PierianDx’s industry-leading genomic SaaS solutions, CAP and CLIA accredited laboratory, and shared knowledgebase are used by health systems, cancer centers and commercial laboratories worldwide driving the most integrated approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx has rapidly become the trusted source of ‘wisdom’ in every advanced genomic report.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $74.0M
- Funding stage: M&A
- Last round: Debt Financing (Nov 2021)
- Website: pieriandx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/pieriandx-61015 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.